Business
IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into 2026Reported Phase 2 interim clinical data for darovasertib and crizotinib combination in MUM; subject to FDA guidance, targeting initiation of potential registrational trial for Daro + Crizo in MUM in Q1 2023Reported preliminary clinical proof-of-concept supporting potential darovasertib use in (neo)adjuvant uveal melanoma; targeting initiation of company-sponsored trial for Daro in neoadjuvant UM in Q4 2022Initiated IDE397 Phase 2 monotherapy expansion cohorts and Phase 1 combination dose escalation cohorts with pemetrexed and taxanes in MTAP-null tumorsTargeting IND filing in Q4 2022 for PARG development candidate IDE161Targeting First-in-Human Phase 1 study initiation in H1 2023 for Pol Theta Helicase inhibitor development candidate, in collaboration with GSK, for solid tumors with HRDHosting IDEAYA Investor R&D Day on Monday, December 12, 2022 at 8:00 am ETSOUTH SAN FRANCISCO, Calif., Nov. 8, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2022.\n\n \n \n \n \n \n \n\n \n\"Our clinical portfolio is maturing, with four potential first-in-class clinical-stage programs anticipated in the first half of 2023 – darovasertib (PKC), IDE397 (MAT2A), IDE161 (PARG) and our Pol Theta Helicase inhibitor development candidate. This broad pipeline of precision medicine therapeutics reflects our commitment to develop transformative therapies with the potential to improve patient lives,\" said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. \"We have built a unique platform in synthetic lethality and an organization with the capabilities to effectively discover and advance our growing preclinical and clinical precision medicine oncology pipeline. Importantly, we own or control all development and commercial rights and interests in our three most advanced programs,\" continued Mr. Hata.\nIDEAYA's most advance clinical program is darovasertib, a potential first-in-class small molecule oral protein kinase C (PKC) in...